Who Buys Diltiazem from India — 298 Importers Behind a $18.0M Market

The 298 buyers of Diltiazem imported from India can be categorized into several segments:

1. Distributors: Entities like EVERSANA LIFE SCIENCE SERVICES and TEVA PHARMACEUTICALS USA, INC. fall into this category. They purchase large quantities to supply to various healthcare providers, pharmacies, and hospitals. Their buying behavior is characterized by bulk orders and a high repeat purchase rate, ensuring a steady supply chain.

2. Contract Manufacturers: Companies such as MYLAN PHARMACEUTICALS INC. and EUGIA US LLC are contract manufacturers. They procure Diltiazem as an active pharmaceutical ingredient (API) for the production of finished dosage forms. Their procurement patterns are aligned with production schedules and demand forecasts, often involving large, periodic orders.

3. Re-exporters: Entities like MARCAN PHARMACEUTICALS INC. in Canada may act as re-exporters, importing Diltiazem from India and then exporting to other markets. Their buying behavior includes purchasing in bulk to benefit from economies of scale and maintaining a diverse supplier base to meet varying international standards.

Each segment exhibits distinct purchasing behaviors: distributors focus on maintaining consistent inventory levels to meet client demands, contract manufacturers align purchases with production cycles, and re-exporters strategize purchases based on global market demands and regulatory requirements.

For the top five importing countries, the import regulations for Diltiazem are as follows:

The demand for Diltiazem in importing countries is driven by several factors:

1. Disease Prevalence: Diltiazem is primarily used to treat hypertension and angina. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, accounting for approximately 17.9 million deaths annually as of 2023. The high prevalence of these conditions necessitates a steady demand for effective treatments like Diltiazem.

2. Government Healthcare Programs and Universal Health Coverage (UHC): Many countries are expanding their UHC programs, increasing access to essential medicines. For instance, the WHO emphasizes the importance of including essential medicines in UHC schemes to ensure equitable access.

3. WHO Essential Medicines List (EML) Procurement: Diltiazem is listed on the WHO EML, guiding countries in their procurement processes to prioritize essential medicines. This inclusion facilitates tender-based purchasing, ensuring that governments and healthcare institutions procure Diltiazem to meet public health needs.

With 298 buyers across 71 countries, the market for Diltiazem imported from India demonstrates robust demand, influenced by global health initiatives and the ongoing need to manage cardiovascular diseases effectively.

The 298 buyers of Diltiazem imported from India can be categorized into several segments:

1. Distributors: Entities like EVERSANA LIFE SCIENCE SERVICES and TEVA PHARMACEUTICALS USA, INC. fall into this category. They purchase large quantities to supply to various healthcare providers, pharmacies, and hospitals. Their buying behavior is characterized by bulk orders and a high repeat purchase rate, ensuring a steady supply chain.

2. Contract Manufacturers: Companies such as MYLAN PHARMACEUTICALS INC. and EUGIA US LLC are contract manufacturers. They procure Diltiazem as an active pharmaceutical ingredient (API) for the production of finished dosage forms. Their procurement patterns are aligned with production schedules and demand forecasts, often involving large, periodic orders.

3. Re-exporters: Entities like MARCAN PHARMACEUTICALS INC. in Canada may act as re-exporters, importing Diltiazem from India and then exporting to other markets. Their buying behavior includes purchasing in bulk to benefit from economies of scale and maintaining a diverse supplier base to meet varying international standards.

Each segment exhibits distinct purchasing behaviors: distributors focus on maintaining consistent inventory levels to meet client demands, contract manufacturers align purchases with production cycles, and re-exporters strategize purchases based on global market demands and regulatory requirements.

For the top five importing countries, the import regulations for Diltiazem are as follows:

The demand for Diltiazem in importing countries is driven by several factors:

1. Disease Prevalence: Diltiazem is primarily used to treat hypertension and angina. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, accounting for approximately 17.9 million deaths annually as of 2023. The high prevalence of these conditions necessitates a steady demand for effective treatments like Diltiazem.

2. Government Healthcare Programs and Universal Health Coverage (UHC): Many countries are expanding their UHC programs, increasing access to essential medicines. For instance, the WHO emphasizes the importance of including essential medicines in UHC schemes to ensure equitable access.

3. WHO Essential Medicines List (EML) Procurement: Diltiazem is listed on the WHO EML, guiding countries in their procurement processes to prioritize essential medicines. This inclusion facilitates tender-based purchasing, ensuring that governments and healthcare institutions procure Diltiazem to meet public health needs.

With 298 buyers across 71 countries, the market for Diltiazem imported from India demonstrates robust demand, influenced by global health initiatives and the ongoing need to manage cardiovascular diseases effectively.